Compare GLDD & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | EVO |
|---|---|---|
| Founded | 1890 | 1993 |
| Country | United States | Germany |
| Employees | 1096 | 4766 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2007 | N/A |
| Metric | GLDD | EVO |
|---|---|---|
| Price | $16.95 | $3.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $7.00 |
| AVG Volume (30 Days) | ★ 2.3M | 122.2K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $9.01 | $7.13 |
| P/E Ratio | $15.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.51 | $2.84 |
| 52 Week High | $16.99 | $4.80 |
| Indicator | GLDD | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 68.94 | 36.39 |
| Support Level | $14.60 | $2.87 |
| Resistance Level | $16.99 | $3.78 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 90.91 | 9.29 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.